Irbesartan: Review of pharmacology and comparative properties

Canadian Journal of Clinical Pharmacology

Volumn 7, Issue 1, 2000, Pages 22-31

  Adams, Michael A ^a   Trudeau, Luc ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Angiotensin; Angiotensin II type 1 receptor blockers; Irbesartan; Losartan; Renin angiotensin system

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERACTION; DRUG METABOLISM; FOOD DRUG INTERACTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; REVIEW; SIDE EFFECT;

EID: 0034053380     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Turgeon J. Pharmacokinetics of angiotensin II type 1 receptor antagonists: focus on losartan, candesartan cilexetil and valsartan. Can J Clin Pharmacol 1998;5:14-22.
2. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998;31:1311-6.
3. Marino MR, Langenbacher K, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998;38:246-55.
4. Belz GG, Butzer R, Mang C, Kober C, Mutschler E. Greater extent and duration of the inhibitory effect of irbesartan on angiotensin II challenge in man compared to losartan and valsartan. Eur J Clin Pharmacol. 1998;54:A8. (Abst)
5. 1 receptor antagonists. J Am Coll Cardiol 1999;33(Suppl A):298A. (Abst)
6. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998;11:445-53.
7. Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators. Clin Ther 1998;20:398-409.
8. Unger T, Chung O, Csikos T, et al. Angiotensin receptors. J Hypertens 1996;14(Suppl):S95-103.
9. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
10. Laffel L, Price D, Porter L, Hollenberg N. Appropriate intrarenal angiotensin II action in patients with insulin-dependent diabetes mellitus (IDDM). J Am Soc Nephrol 1997;8:A1606. (Abst)
11. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275-9.
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
13. Husain A. The chymase-angiotensin system in humans. J Hypertens 1993;11:1155-9.
14. Pylypchuk GB. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998;32:1060-6.
15. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-51.
16. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-34.
17. 1-receptor blockers in isolated vessels of different origin. Hypertension 1999;33:1406-13.
18. Vachharajani NN, Shyu WC, Chando TJ, Everett DW, Greene DS, Barbhaiya RH. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 1998;38:702-7.
19. Vachharajani NN, Shyu WC, Mantha S, et al. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol 1998;38:433-6.
20. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite, EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-9.
21. Cozaar® (Losartan Potassium Tablets) Product Monograph. Kirkland: Merck, Sharpe & Dohme Canada, 1998.
22. Goa KL, Wagstaff AJ. Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996;51:820-45.
23. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299-311.
24. Criscione L, Bradley WA, Buhlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 1995;13:230-50.
25. Van Lier JJ, van Heiningen PNM, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997;11(Suppl 2):S27-8.
26. Atacand™ (Candesartan Cilexetil Tablets) Product Monograph. Mississauga: Astra Pharma Inc, 1998.
27. Riddell JG. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil. J Hum Hypertens 1997;11(Suppl 2):S29-30.
28. Micardis® (telmisartan tablets) Product Monograph. Burlington: Boehringer Ingelheim Canada, Ltd, 1999.
29. Teveten® (eprosartan mesylate) Product Monograph. Scarborough: Solvay Pharma, 1999.
30. Marino MR, Langenbacher K, Ford NF, Uderman HD. Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects. Clin Pharmacol Ther 1997;61:207.
31. Stangier J, Heinzel G, Capf S, et al. Clinical pharmacokinetics of telmisartan. 2nd International Symposium on Angiotensin-II Antagonism, London, February 15-18, 1999.
32. Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998;26:408-17.
33. Marino MR, Lagenbacher KM, Mangold B, Gielsdorf W, Ford N. Lack of drug interactions with irbesartan: a summary of five pharmacokinetic studies. J Hypertens 1998;16(Suppl 2):S248.
34. Marino MR, Vachharajani NN, for the Multicenter Investigators. The pharmacokinetics of irbesartan are not altered in special populations. Am J Hypertens 1998;11:101A. (Abst)
35. Vachharajani N, Shyu WC, Smith R, Chang S-Y, Greene D, Barbhaiya R. The effects of age on the pharmacokinetics of irbesartan. J Clin Pharmacol 1997;37:872.
36. Sica DA, Marino MR, Hammett JL, et al. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997;62:610-8.
37. Marino MR, Lagenbacher KM, Raymond RH, Ford NF, Lasseter KC. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998;38:347-56.
38. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997;157:2413-46.
39. Ribstein J, Picard A, Amagnac C, Bouroudian M, Sissmann J, Mimran A. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normontensive subjects. J Hypertens 1997;15(Suppl):S117-8.
40. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997;15:1511-8.
41. Man in't Veld AJ. Clinical overview of irbesartan: expanding the therapeutic window in hypertension. J Hypertens 1997;15(Suppl 7):S27-33.
42. Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension. Clin Drug Invest 1998;15:217-27.
43. Pouleur HG. Clinical overview of irbesartan. A new angiotensin II receptor antagonist. Am J Hypertens 1997;10:318S-24S.
44. Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12:414-7.
45. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998;7:53-9.
46. Gradman AH, Lewin A, Bowling BT, et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Heart Dis 1999;1:52-7.
47. Mallion JM, Siche JP, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-64.
48. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Co-operative Research Group. JAMA 1991;265:3255-64.
49. MRC Trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985;291:97-104.
50. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979;242:2562-71.
51. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.
52. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 1998;352:1801-7.
53. Culman J, Hartling S, von Heyer C, Rascher W, Unger T. Effects of irbesartan and losartan administered peripherally or centrally on vasopressin release, drinking response, and c-Fos expression in the rat brain. J Hypertens 1998;16(Suppl 2):S114.
54. 2-induced vasoconstriction in canine coronary arteries. Eur Heart J 1998;19:187.
55. Kahan T, Malmqvist K, Edner M, Held C, Osbakken M. Rate and extent of left ventricular hypertrophy regression: a comparison of angiotensin II blockade with irbesartan and beta-blockade. J Am Coll Cardiol 1998;31:212A. (Abst)
56. Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens 1998;16(Suppl 7):S23-9.
57. 1 receptor blockade on survival, systemic and coronary hemodynamics and cardiac remodeling in post-ischemic heart failure in rats. Circulation 1997;96(Suppl 8):644.
58. Vijay N, Alhaddad IA, Marty Denny D, et al. Irbesartan compared with lisinopril in patients with mild to moderate heart failure. J Am Coll Cardiol 1998;31:68A. (Abst)
59. Tonkon M, Awan N, Niazi I, et al. Irbesartan combined with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure. J Am Coll Cardiol 1998;31:188A. (Abst)
60. Havranek EP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy or irbesartan in heart failure. Circulation 1997;96:452. (Abst)
61. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997:349:747-52.
62. Yusuf S, Maggioni AP, Held P, Rouleau J-L. Effects of candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD). Circulation 1997:96(Suppl):I452.
63. Cohn JN, Tognoni G, Glazer RD, Spormann D, Hester A. Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail 1999:5:155-60.
64. Pitt B, Poole-Wilson P, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the losartan heart failure survival study - ELITE II. J Card Fail 1999:5:146-54.
65. Lim PO, Nys M, Naas AOA, Struthers AD, Osbakken M, MacDonald TM. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999;33:713-8.
66. 1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999;12:28-34.
67. Pechère-Bertschi A, Nussberger J, Decosterd L, et al. Renal response to the angiotensin II receptor subtype I antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998;16:385-93.
68. Pohl M, Cooper M, Ulrey J, Pauls J, Rohse R. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria. Am J Hypertens 1997;10:105A. (Abst)
69. O'Donnell MP, Crary CS, Oda H, Kasiske BL, Powell JR, Keane WF. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. Kidney Int 1997;53(Suppl 63):S218-20.
70. Crary GS, Swan SK, O'Donnell MP, et al. The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. J Am Soc Nephrol 1995;6:1295-9.
71. Porush JG, Beri T, Anzalone DA, Rohde R. Multi-center collaborative trial of angiotensin II receptor antagonism on morbidity, mortality and renal function in hypertensive type II diabetic patients with nephropathy. Am J Hypertens 1998;11:73A. (Abst)
72. Simon TA, Gelarden RT, Owens D, Freitag SA, Kassler-Taub KB. The safety of irbesartan in the treatment of mild-to-moderate hypertension: results of randomized, double-blind, placebo-controlled studies. Am J Cardiol 1998;82:179-82.
73. Hansson L, Smith DHG, Reeves R, Lapuerta P. Headache in mild-to-moderate hypertension and its reduction by irbesartan. Arch Intern Med. (In press)